ArticleNature communications2023
Monkeypox virus-infected individuals mount comparable humoral immune responses as Smallpox-vaccinated individuals.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 44 citations in OpenAlex.
- Current Strategies for Selecting Recombinant Orthopoxvirus Proteins for Immunobiological and Diagnostic Applications.Viruses · 2026Review
- Waning humoral immunity following monkeypox virus infection and vaccination, Canada, 2020 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Observational
- Mpox comprehensive assessment for responsive immunisation in emergency outbreaks (MpoxCARE): study protocol.BMC infectious diseases · 2026Article
- Differentiating mpox infection and vaccination using a validated multiplex orthopoxvirus IgG serology assay.Journal of clinical microbiology · 2026Article
- Sero-genomic evidence for occult mpox exposure in healthy Nigerian adults.Nature communications · 2026Article
- Serological evidence uncovers undocumented mpox exposure in febrile patients in Nigeria.Frontiers in public health · 2026Article
- Serological differentiation between Mpox infection and vaccine-induced immunity: a mini-review.Frontiers in immunology · 2026Review
- A retrospective comparative diagnostic evaluation of three commercial qPCR kits for the diagnosis of mpox virus on an enriched sample set.Frontiers in cellular and infection microbiology · 2026Article
- Comparative humoral profiles in mpox cases, survivors, and vaccinated individuals reveal correlates of protection against MPXV.Cell reports. Medicine · 2025Article
- Potent neutralization by antibodies targeting the MPXV A28 protein.Nature communications · 2025Article
- Machine learning-supported framework for the classification of mpox infection and MVA immunization from multiplexed serology data.Nature communications · 2025Article
- Immune profiling of mpox survivors reveals divergent durability of antibody and T cell responses.Nature communications · 2025Article
- Developing accessible and affordable tests to support mpox immunosurveillance and vaccine studies.Emerging microbes & infections · 2025Article
- Rational mpox vaccine design: immunogenicity and protective effect of individual and multicomponent proteins in mice.Emerging microbes & infections · 2025Article
- Review
- The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.Journal of virology · 2025Observational
- Serological differentiation between naturally acquired mpox and MVA-BN-vaccine induced antibody responses using ratios of MPXV and VACV antigen pairs in the MSD immunoassay.Microbiology spectrum · 2025Article
- Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model.Nature communications · 2025Article
- Multivalent mpox protein nanoparticle vaccines confer cross-protection against orthopoxvirus infection.PLoS pathogens · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In early 2022, a cluster of monkeypox virus (MPXV) infection (mpox) cases were identified within the UK with no prior travel history to MPXV-endemic regions. Subsequently, case numbers exceeding 80,000 were reported worldwide, primarily affecting gay, bisexual, and other men who have sex with men (GBMSM). Public health agencies worldwide have offered the IMVANEX Smallpox vaccination to these individuals at high-risk to provide protection and limit the spread of MPXV. We have developed a comprehensive array of ELISAs to study poxvirus-induced antibodies, utilising 24 MPXV and 3 Vaccinia virus (VACV) recombinant antigens. Panels of serum samples from individuals with differing Smallpox-vaccine doses and those with prior MPXV infection were tested on these assays, where we observed that one dose of Smallpox vaccination induces a low number of antibodies to a limited number of MPXV antigens but increasing with further vaccination doses. MPXV infection induced similar antibody responses to diverse poxvirus antigens observed in Smallpox-vaccinated individuals. We identify MPXV A27 as a serological marker of MPXV-infection, whilst MPXV M1 (VACV L1) is likely IMVANEX-specific. Here, we demonstrate analogous humoral antigen recognition between both MPXV-infected or Smallpox-vaccinated individuals, with binding to diverse yet core set of poxvirus antigens, providing opportunities for future vaccine (e.g., mRNA) and therapeutic (e.g., mAbs) design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.